INT90699

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 2000
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 4
Total Number 6
Disease Relevance 2.70
Pain Relevance 0.67

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (F12) extracellular space (F12) extracellular region (F12)
Anatomy Link Frequency
plasma 1
blood 1
F12 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 3 99.68 Very High Very High Very High
bradykinin 21 98.72 Very High Very High Very High
Pain 5 79.32 Quite High
cva 4 68.76 Quite High
Antihistamine 33 21.96 Low Low
corticosteroid 15 21.20 Low Low
abdominal pain 16 6.00 Low Low
antagonist 12 5.00 Very Low Very Low Very Low
b2 receptor 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hereditary Angioedema 401 97.84 Very High Very High Very High
Disease 66 94.20 High High
Coagulation Disorder 7 93.28 High High
Endotoxemia 1 92.56 High High
Hypertension 1 92.04 High High
INFLAMMATION 2 91.48 High High
Pressure And Volume Under Development 231 84.56 Quite High
Thrombosis 3 83.56 Quite High
Targeted Disruption 1 82.56 Quite High
Pain 5 79.32 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Pharmacological regulation of factor XII activation may be a new target to control pathological coagulation.
Regulation (regulation) of factor XII associated with inflammation
1) Confidence 0.45 Published 2008 Journal Biochem. Pharmacol. Section Title Doc Link 17996217 Disease Relevance 0.45 Pain Relevance 0.08
In some cases, the persistent production of BK due to the deficiency of the blood protein C1-inhibitor, which controls FXII, is detrimental to the survival of the patients with hereditary angioedema (HAE).
Regulation (controls) of FXII in blood associated with hereditary angioedema and bradykinin
2) Confidence 0.10 Published 2009 Journal Cardiovascular & hematological agents in medicinal chemistry Section Abstract Doc Link 19689262 Disease Relevance 0.63 Pain Relevance 0.59
Based on these findings, it was suggested that the FXII Thr309Lys mutation (referred to as Thr328Lys by adding the leader protein) is a gain-of-function mutation that markedly increases FXII amidolytic activity but that does not alter FXII plasma levels [6].
Neg (not) Regulation (alter) of FXII in plasma
3) Confidence 0.04 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2919521 Disease Relevance 0.30 Pain Relevance 0
By following a functional hypothesis that the genetic defect might be located in the coagulation factor XII (FXII) gene the factor XII gene on chromosome 5 was then selectively investigated [11].
Regulation (coagulation) of FXII
4) Confidence 0.04 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2919521 Disease Relevance 0.72 Pain Relevance 0
The location of these mutations is the same locus, 5q33-qter of the Hageman factor or coagulation FXII gene (Online Mendelian Inheritance in Man # 610619).
Regulation (coagulation) of FXII
5) Confidence 0.03 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2919521 Disease Relevance 0.59 Pain Relevance 0
DNA sequencing revealed no abnormality in 3 patients in the coding region of the gene encoding C1 inhibitor or in the 5' flanking regions of the genes encoding C1 inhibitor and factor XII.
Neg (no) Regulation (abnormality) of factor XII
6) Confidence 0.02 Published 2000 Journal J. Allergy Clin. Immunol. Section Body Doc Link 10984376 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox